Navigation Links
Globus Medical Announces Record 2nd Quarter 2007 Results
Date:8/27/2007

AUDUBON, Pa., Aug. 27 /PRNewswire/ -- Globus Medical, Inc., the largest privately held spinal implant manufacturer in the world, today announced record revenue for the quarter ending June 30, 2007. The company recorded revenues of $30.2 million for the second quarter -- an increase of 52% over the $19.9 million it achieved in the same quarter a year ago. The announcement follows on the heels of $110 million in series E financing to fund Globus' continued rapid growth.

"The record results were driven by a major expansion of the company's sales and distribution footprint, and the introduction of several new products across its fusion, MIS and biomaterials portfolio," said Rick Kienzle, Executive Vice President of Sales and Marketing, Globus Medical. "In addition, strong market acceptance of our Revere(TM) pedicle screw system continues to fuel significant conversions in our established and new markets."

During the second quarter, Globus Medical added several highly-experienced sales professionals in key U.S. markets, bringing the total number of people added to its sales and distribution infrastructure in 2007 to 25.

So far in 2007, Globus has introduced six new systems that represent significant technological advancements in fusion, MIS and biomaterials. Additionally, in the area of motion preservation, the company announced two "world's first" surgeries using its transforaminal and posterior disc replacement systems.

Globus Medical also entered the biomaterial segment during the second quarter with the introduction of the NuBone(TM) Osteoinductive Bone Graft Product Line, the first of several new biomaterial initiatives planned for the next 12 months. The launch of Globus Medical's MARS(TM) Minimally Invasive Retractor System filled out its MIS product portfolio, further securing the company's leadership position in MIS technology and products. Both MIS and biomaterials are key initiatives in Globus Medical's strategy to innovate across the complete suite of products.

"The pace and research behind our product development engine continues to set Globus Medical apart by enabling technological advancements across the complete spectrum of spinal products," Dave Demski, Chief Financial Officer, Globus Medical said. "This innovation is at the heart of Globus Medical and, coupled with the expansion in the sales force, is accelerating our penetration of new markets and driving growth."

About Globus Medical, Inc.

Globus Medical, Inc. is one of the ten largest spinal implant manufacturers in the world, with more than $120 million in annualized revenues. Based in Audubon, Pa., the privately held company was founded in 2003 by an experienced team of spine professionals with a shared vision to create products that enable spine surgeons to employ both fusion and non-fusion solutions to promote healing in patients with spinal disorders. Globus Medical has a full portfolio of spinal fusion products, burgeoning initiatives in biomaterials development and minimally invasive approaches, and is among the world leaders in the development of motion sparing technology. Additional information can be accessed at http://www.globusmedical.com.

Contact:

Sara Brown Meehan

415-595-9872

sbmeehan@levick.com


'/>"/>
SOURCE Globus Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. ... pleased to report compelling safety and clinical data from its ... type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment ... ... establishing a complete safety profile at 6 months and showed ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... as Chief Executive Officer with Avomeen Analytical Services. Harvill is a distinguished life ... operations. , Avomeen is a leader in a wide range of services ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the fight against cancer, autoimmune disease and more through a single-cell precision engineering ... and proteomics analysis platform developed in the laboratory of Dr. James Heath ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small ... samples with limited tumor content in a large background of normal or wild ... the need for reliable detection of low abundance somatic mutations, particularly in small ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:2/28/2017)...   Acuant , a leading provider of data ... to new and core technologies building upon the acquisition ... and desktop Acuant FRM TM facial recognition and ... time manual review of identity documents by accredited professionals. ... and most accurate capture software to streamline workflows by ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
Breaking Biology News(10 mins):